研究园简易版 · 经典书籍 · 期刊文章 · 有原文 · 完整版(可多选筛选、搜索) · 首页
2024 年 · Clinical Trials(临床试验)
119 篇,新的在前。点标题看作者和摘要。回到 2024 年
- Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials? · SMMR · 2024-12-12 · 在第 1 页
- Approximation to the optimal allocation for response adaptive designs · SMMR · 2024-12-12 · 在第 1 页
- Linear Mixed Modeling of Federated Data When Only the Mean, Covariance, and Sample Size Are Available · SiM · 2024-12-11 · 在第 2 页
- Estimating marginal treatment effect in cluster randomized trials with multi-level missing outcomes · Biometrics · 2024-12-04 · 在第 2 页
- An adaptive enrichment design using Bayesian model averaging for selection and threshold-identification of predictive variables · Biometrics · 2024-12-03 · 在第 2 页
- Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data · SiM · 2024-11-25 · 在第 3 页
- The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints · SiM · 2024-11-25 · 在第 3 页
- Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints · SiM · 2024-11-25 · 在第 3 页
- Model-based optimal randomization procedure for treatment–covariate interaction tests · SMMR · 2024-11-25 · 在第 3 页
- Covariate-adjusted response-adaptive designs for semiparametric survival models · SMMR · 2024-11-25 · 在第 3 页
- A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods · SiM · 2024-11-17 · 在第 4 页
- How to achieve model-robust inference in stepped wedge trials with model-based methods? · Biometrics · 2024-11-05 · 在第 5 页
- Estimating an adjusted risk difference in a cluster randomized trial with individual-level analyses · SMMR · 2024-11-05 · 在第 5 页
- Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule · SiM · 2024-11-05 · 在第 5 页
- Dose Individualization for Phase I Cancer Trials With Broadened Eligibility · SiM · 2024-10-31 · 在第 5 页
- Statistical methods for clinical trials interrupted by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic: A review · SMMR · 2024-10-30 · 在第 5 页
- Estimands and Cumulative Incidence Function Regression in Clinical Trials: Some New Results on Interpretability and Robustness · SiM · 2024-10-29 · 在第 5 页
- Leveraging information from secondary endpoints to enhance dynamic borrowing across subpopulations · Biometrics · 2024-10-23 · 在第 5 页
- Comparison of statistical methods for the analysis of patient-reported outcomes in randomised controlled trials: A simulation study · SMMR · 2024-10-23 · 在第 5 页
- Phase I/II Design for Selecting Subgroup‐Specific Optimal Biological Doses for Prespecified Subgroups · SiM · 2024-10-18 · 在第 6 页
- Causal Inference for Continuous Multiple Time Point Interventions · SiM · 2024-10-17 · 在第 6 页
- A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin · SiM · 2024-10-17 · 在第 6 页
- A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies · SMMR · 2024-10-14 · 在第 6 页
- Group sequential testing of a treatment effect using a surrogate marker · Biometrics · 2024-10-08 · 在第 6 页
- Enhancing DHA supplementation adherence: A Bayesian approach with finite mixture models and irregular interim schedules in adaptive trial designs · SMMR · 2024-10-04 · 在第 7 页
- ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications · Biometrics · 2024-10-03 · 在第 7 页
- LEAP: the latent exchangeability prior for borrowing information from historical data · Biometrics · 2024-09-27 · 在第 8 页
- Designing cancer screening trials for reduction in late-stage cancer incidence · Biometrics · 2024-09-20 · 在第 8 页
- Transportability of model‐based estimands in evidence synthesis · SiM · 2024-09-18 · 在第 8 页
- Group Response‐Adaptive Randomization With Delayed and Missing Responses · SiM · 2024-09-16 · 在第 8 页
- Asymptotic Confidence Interval, Sample Size Formulas and Comparison Test for the Agreement Intra‐Class Correlation Coefficient in Inter‐Rater Reliability Studies · SiM · 2024-09-16 · 在第 8 页
- Adjusting for incomplete baseline covariates in randomized controlled trials: a cross-world imputation framework · Biometrics · 2024-09-13 · 在第 8 页
- A Bayesian latent-subgroup platform design for dose optimization · Biometrics · 2024-09-10 · 在第 9 页
- A Causal Mediation Approach to Account for Interaction of Treatment and Intercurrent Events: Using Hypothetical Strategy · SiM · 2024-09-05 · 在第 9 页
- Performance of mixed effects models and generalized estimating equations for continuous outcomes in partially clustered trials including both independent and paired data · SiM · 2024-09-04 · 在第 9 页
- A hybrid approach to sample size re‐estimation in cluster randomized trials with continuous outcomes · SiM · 2024-08-28 · 在第 9 页
- Group sequential designs for clinical trials when the maximum sample size is uncertain · SiM · 2024-08-21 · 在第 9 页
- Principal quantile treatment effect estimation using principal scores · SiM · 2024-08-19 · 在第 10 页
- New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models · SMMR · 2024-08-19 · 在第 10 页
- Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints · SiM · 2024-08-07 · 在第 10 页
- Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint · SMMR · 2024-08-06 · 在第 10 页
- Measuring the individualization potential of treatment individualization rules: Application to rules built with a new parametric interaction model for parallel-group clinical trials · SMMR · 2024-08-06 · 在第 10 页
- Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design · SiM · 2024-07-29 · 在第 11 页
- Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data · SiM · 2024-07-25 · 在第 11 页
- Judith ter Schure’s contribution to the Discussion of ‘Safe testing’ by Grünwald, de Heide, and Koolen · JRSSB · 2024-07-09 · 在第 12 页
- Determining sample size in a personalized randomized controlled ( PRACTical ) trial · SiM · 2024-07-09 · 在第 12 页
- A sequential, multiple assignment, randomized trial design with a tailoring function · SiM · 2024-07-08 · 在第 12 页
- Marco Cattaneo's contribution to the Discussion of “Safe testing” by Grünwald, de Heide, and Koolen · JRSSB · 2024-07-02 · 在第 12 页
- Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials · SiM · 2024-06-24 · 在第 13 页
- Improved mortality analysis in early‐phase dose‐ranging clinical trials for emergency medical diseases using Bayesian time‐to‐event models with active comparators · SiM · 2024-06-17 · 在第 13 页
- Assurance methods for designing a clinical trial with a delayed treatment effect · SiM · 2024-06-16 · 在第 13 页
- A multi‐arm multi‐stage platform design that allows preplanned addition of arms while still controlling the family‐wise error · SiM · 2024-06-16 · 在第 13 页
- REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors · SiM · 2024-06-10 · 在第 14 页
- Bayesian transition models for ordinal longitudinal outcomes · SiM · 2024-06-09 · 在第 14 页
- Adding experimental treatment arms to multi‐arm multi‐stage platform trials in progress · SiM · 2024-06-09 · 在第 14 页
- Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs · SiM · 2024-06-06 · 在第 14 页
- A seamless phase II/III design with dose optimization for oncology drug development · SiM · 2024-06-06 · 在第 14 页
- Group sequential methods based on supremum logrank statistics under proportional and nonproportional hazards · SMMR · 2024-06-05 · 在第 14 页
- Robust analysis of stepped wedge trials using composite likelihood models · SiM · 2024-06-04 · 在第 14 页
- Understanding an impact of patient enrollment pattern on predictability of central (unstratified) randomization in a multi‐center clinical trial · SiM · 2024-06-03 · 在第 15 页
- Optimal designs using generalized estimating equations in cluster randomized crossover and stepped wedge trials · SMMR · 2024-05-30 · 在第 15 页
- Fractional accumulative calibration‐free odds (f‐aCFO) design for delayed toxicity in phase I clinical trials · SiM · 2024-05-30 · 在第 15 页
- Maintaining the validity of inference from linear mixed models in stepped-wedge cluster randomized trials under misspecified random-effects structures · SMMR · 2024-05-29 · 在第 15 页
- Sample size determination for prediction models via learning‐type curves · SiM · 2024-05-27 · 在第 16 页
- Design of randomized clinical trials with a binary endpoint: Conditional versus unconditional analyses of a two‐by‐two table · SiM · 2024-05-23 · 在第 16 页
- Demystifying estimands in cluster-randomised trials · SMMR · 2024-05-23 · 在第 16 页
- Efficient Nonparametric Estimation of Stochastic Policy Effects with Clustered Interference · JASA · 2024-05-20 · 在第 16 页
- Sample size calculation for comparing two screening tests when the gold standard is missing at random · SiM · 2024-05-15 · 在第 16 页
- Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization · SiM · 2024-05-15 · 在第 17 页
- A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials · SiM · 2024-05-14 · 在第 17 页
- Novel non‐linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods · SiM · 2024-05-10 · 在第 17 页
- Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity · SMMR · 2024-05-08 · 在第 17 页
- Adaptive designs in public health: Vaccine and cluster randomized trials go Bayesian · SiM · 2024-05-08 · 在第 17 页
- Causal inference for time-to-event data with a cured subpopulation · Biometrics · 2024-05-06 · 在第 17 页
- Sample size and power calculation for testing treatment effect heterogeneity in cluster randomized crossover designs · SMMR · 2024-05-01 · 在第 17 页
- Causal rule ensemble method for estimating heterogeneous treatment effect with consideration of prognostic effects · SMMR · 2024-04-27 · 在第 17 页
- The performance of marginal structural models for estimating risk differences and relative risks using weighted univariate generalized linear models · SMMR · 2024-04-24 · 在第 17 页
- Statistical considerations in model‐based dose finding for binary responses under model uncertainty · SiM · 2024-04-11 · 在第 18 页
- Well-spread samples with dynamic sample sizes · Biometrics · 2024-04-09 · 在第 18 页
- Methods for non-proportional hazards in clinical trials: A systematic review · SMMR · 2024-04-09 · 在第 18 页
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling · SiM · 2024-04-09 · 在第 18 页
- A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies · SMMR · 2024-04-04 · 在第 18 页
- Confidence intervals for odds ratio from multistage randomized phase II trials · SiM · 2024-04-02 · 在第 19 页
- A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart · SiM · 2024-04-02 · 在第 19 页
- Sample size estimation for stratified cluster randomization trial with survival endpoint · SMMR · 2024-03-29 · 在第 19 页
- Sample size adaptation designs and efficiency comparison with group sequential designs · SiM · 2024-03-28 · 在第 19 页
- A nonparametric relative treatment effect for direct comparisons of censored paired survival outcomes · SiM · 2024-03-28 · 在第 19 页
- Optimal allocation strategies in platform trials with continuous endpoints · SMMR · 2024-03-20 · 在第 20 页
- Changing interim monitoring in response to internal clinical trial data · Biometrics · 2024-03-13 · 在第 20 页
- Simultaneous inference procedures for the comparison of multiple characteristics of two survival functions · SMMR · 2024-03-11 · 在第 20 页
- Two-phase designs with failure time processes subject to nonsusceptibility · Biometrics · 2024-03-06 · 在第 21 页
- BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations · SMMR · 2024-03-06 · 在第 21 页
- On the distribution of the power function for the scale parameter of exponential families · SiM · 2024-03-05 · 在第 21 页
- A class of computational methods to reduce selection bias when designing Phase 3 clinical trials · SiM · 2024-03-05 · 在第 21 页
- Use of win time for ordered composite endpoints in clinical trials · SiM · 2024-02-28 · 在第 21 页
- A framework for testing non-inferiority in a three-arm, sequential, multiple assignment randomized trial · SMMR · 2024-02-23 · 在第 22 页
- Doubly adaptive biased coin design to improve Bayesian clinical trials with time‐to‐event endpoints · SiM · 2024-02-22 · 在第 22 页
- A rank-based approach to evaluate a surrogate marker in a small sample setting · Biometrics · 2024-02-22 · 在第 22 页
- Are the tests overpowered or underpowered? A unified solution to correctly specify type I errors in design of clinical trials for two sample proportions · SiM · 2024-02-19 · 在第 22 页
- Randomized phase II selection design with order constrained strata · Biometrics · 2024-02-16 · 在第 23 页
- A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison · Biometrics · 2024-02-16 · 在第 23 页
- Torben Martinussen’s contribution to the Discussion of ‘Parameterizing and simulating from causal models’ by Evans and Didelez · JRSSB · 2024-02-15 · 在第 23 页
- Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials · SiM · 2024-02-13 · 在第 23 页
- A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design · SiM · 2024-02-12 · 在第 23 页
- Point estimation, confidence intervals, and P‐values for optimal adaptive two‐stage designs with normal endpoints · SiM · 2024-02-10 · 在第 23 页
- Bayesian hierarchical modeling in interim futility analysis for two parallel clinical trials · SiM · 2024-02-10 · 在第 23 页
- A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies · SiM · 2024-02-10 · 在第 24 页
- Covariate adjustment in Bayesian adaptive randomized controlled trials · SMMR · 2024-02-07 · 在第 24 页
- A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II · SMMR · 2024-02-07 · 在第 24 页
- Multiply robust generalized estimating equations for cluster randomized trials with missing outcomes · SiM · 2024-02-05 · 在第 24 页
- Statistical-computational trade-offs in tensor PCA and related problems via communication complexity · AoS · 2024-02-01 · 在第 24 页
- Effective sample size: A measure of individual uncertainty in predictions · SiM · 2024-01-31 · 在第 25 页
- A statistical framework for planning and analysing test–retest studies of repeatability · SMMR · 2024-01-31 · 在第 25 页
- A comparison of model-free phase I dose escalation designs for dual-agent combination therapies · SMMR · 2024-01-24 · 在第 25 页
- Steady‐state statistical properties and implementation of randomization designs with maximum tolerated imbalance restriction for two‐arm equal allocation clinical trials · SiM · 2024-01-20 · 在第 25 页
- Confidence distributions for treatment effects in clinical trials: Posteriors without priors · SiM · 2024-01-11 · 在第 26 页
- Model-Robust and Efficient Covariate Adjustment for Cluster-Randomized Experiments · JASA · 2024-01-09 · 在第 26 页
- Exact Bias Correction for Linear Adjustment of Randomized Controlled Trials · Econometrica · 2024 · 在第 35 页
- Causal effects of intervening variables in settings with unmeasured confounding · JMLR · 2024 · 在第 37 页